Global Surgical Stents Market Size By Type (Metal, Standard Polymer), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Surgical Stents Market was valued at USD 5.7 billion in 2023 and is projected to surpass USD 9.4 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The market's expansion is primarily driven by the rising prevalence of cardiovascular diseases, urological disorders, and gastrointestinal complications, leading to an increased need for surgical stents.

Advancements in biodegradable and drug-eluting stents, along with the increasing adoption of minimally invasive surgeries (MIS), are further fueling market growth. Moreover, the demand for patient-specific stents, supported by 3D printing technology, is expanding the market’s scope.

Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs)

Cardiovascular diseases are among the leading causes of mortality globally. According to the World Health Organization (WHO), over 17.9 million deaths occur annually due to CVDs. The increasing demand for coronary and peripheral vascular stents to manage heart diseases is significantly propelling market growth.

Growing Preference for Minimally Invasive Surgeries (MIS)

Surgeons and patients increasingly prefer minimally invasive procedures due to their advantages, including reduced recovery time, lower risk of infections, and minimal scarring. Surgical stents, particularly self-expanding and balloon-expandable stents, play a crucial role in MIS.

Technological Advancements in Stent Designs

Manufacturers are introducing biodegradable stents, bioresorbable scaffolds, and drug-eluting stents, which provide better patient outcomes while reducing complications. The development of customized 3D-printed stents is also gaining traction, enhancing procedural success rates.

Restraints

High Cost of Stent Procedures

Despite the rising demand, the high cost of surgical stents, particularly drug-eluting and biodegradable stents, poses a challenge for market expansion. The lack of reimbursement policies in developing regions further restricts access to stent-based treatments.

Stringent Regulatory Approvals

Regulatory bodies like the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) impose strict approval processes for new stents, delaying market entry and increasing development costs.

Opportunities

Growing Demand in Emerging Economies

Countries in Asia-Pacific and Latin America are experiencing significant growth in healthcare infrastructure, increasing the adoption of surgical stents. Government initiatives to improve cardiovascular and urological care are creating lucrative market opportunities.

Integration of AI and Robotics in Surgery

The rise of robot-assisted surgeries and AI-driven diagnostic tools is improving stent placement precision, reducing complications, and expanding adoption rates.

Rising Adoption of Bioresorbable and Biodegradable Stents

The development of next-generation stents that dissolve naturally after fulfilling their function is creating new opportunities. These stents reduce the risk of long-term complications such as late thrombosis.

Market by System Type Insights

Coronary Stents Hold the Largest Market Share

Based on system type, coronary stents accounted for the largest revenue share in 2023. The increasing burden of heart diseases and rising lifestyle-related risk factors such as diabetes, obesity, and hypertension are driving segment growth.

Urological and Gastrointestinal Stents Gaining Momentum

The urological stent segment is expected to witness significant growth, driven by an aging population and increasing cases of kidney stones and ureteral obstructions. The gastrointestinal stent segment is also expanding, particularly for the treatment of colorectal and esophageal strictures.

Market by End-Use Insights

Hospitals Dominate the Market

The hospital segment accounted for the largest share in 2023, as these institutions conduct the majority of stent placement procedures. The rising adoption of advanced stent placement techniques and the presence of specialized surgical units contribute to the segment’s dominance.

Ambulatory Surgical Centers (ASCs) Experiencing Rapid Growth

Ambulatory Surgical Centers are becoming increasingly popular due to lower costs and shorter hospital stays. The increasing preference for outpatient procedures, especially for vascular and urological stents, is fueling market growth.

Market by Regional Insights

North America Leads the Global Market

North America held the largest market share in 2023, driven by high healthcare expenditure, an increasing burden of chronic diseases, and the presence of leading market players. The U.S. dominates this region due to the rapid adoption of cutting-edge stent technologies.

Asia-Pacific to Experience the Fastest Growth

The Asia-Pacific region is projected to witness the highest CAGR during the forecast period, primarily due to growing healthcare infrastructure, increasing awareness about cardiovascular health, and rising medical tourism in countries like India, China, and Japan.

Europe Holds a Significant Share

Europe remains a key market, with Germany, France, and the U.K. leading the region due to strong reimbursement policies and increasing investments in healthcare innovation.

Competitive Scenario

Key players operating in the Global Surgical Stents Market include:

Medtronic plc

Boston Scientific Corporation

Abbott Laboratories

B. Braun Melsungen AG

Terumo Corporation

Cook Medical

MicroPort Scientific Corporation

Becton, Dickinson and Company (BD)

Merit Medical Systems

Cordis Corporation (a Cardinal Health Company)

These companies focus on product innovations, strategic partnerships, mergers & acquisitions, and geographical expansion to maintain a competitive edge.

Key Market Developments

In 2023, Medtronic launched a next-generation drug-eluting stent with enhanced durability and reduced restenosis risk.

In 2022, Boston Scientific Corporation acquired a leading stent technology firm to strengthen its portfolio.

In 2024, Abbott Laboratories announced the development of an advanced bioresorbable stent, expected to enter clinical trials soon.

Scope of Work – Global Surgical Stents Market